The Early Warning Score (EWS) and its modified version, the Modified Early Warning Score (MEWS), are used to identify patients who are at risk for clinical deterioration, but their application in oncology practice has been limited. Learn all about the implementation processes, successes, and challenges of these tools to determine if they could be an asset to your institution. You’ll also review literature supporting the use of these tools and hear about the experiences of two major medical centers that have implemented the scores.

**Target Audience:** Registered Nurses

**Level of Content:** Intermediate

**Coordinator:**
Brenda Shelton, RN, MS, CCRN, AOCN®
Johns Hopkins Hospital
Baltimore, MD
sheltbr@jhmi.edu

**Full Disclosure:**
Nothing to Disclose

**Speaker:**
Mikaela Olsen, RN, MS, AOCNS®
Oncology and Hematology Clinical Nurse Specialist
Sidney Kimmel CCC at Johns Hopkins
Baltimore, MD

**Full Disclosure:**
Nothing to Disclose

**Speaker:**
Kathy Mooney, RN, OCN®, BMTCN™
Johns Hopkins Medical Institutions
Baltimore, MD

**Full Disclosure:**
Nothing to Disclose

**Objectives:**
At the end of this session, participants will be able to:
1. Identify the clinical components of the Early Warning Score and variations used in oncology practice.
2. Describe how the Modified Early Warning Score (MEWS) has been implemented in oncology clinical practice.
3. Reflect in order to give examples of the applicability of the MEWS tool in your current practice setting.